At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 329 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Placebo, BI 409306, and 1 other intervention for Alzheimer Disease. Completed, enrolled 329 participants across 60 sites in 11 countries.
Detailed Summary
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesAustria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJan 2015
Primary CompletionSep 2017
Study CompletionOct 2017
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartJan 21, 2015
Primary CompletionSep 15, 2017
Study CompletionOct 10, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.5 years ago
Interventions
Placebodrug
for blinding purposes
Placebodrug
BI 409306drug
Donepezildrug